Attenuation of immune complex nephritis in NZB/WF1 mice by a prostacyclin analogue
- PMID: 7882569
- PMCID: PMC1534207
- DOI: 10.1111/j.1365-2249.1995.tb05572.x
Attenuation of immune complex nephritis in NZB/WF1 mice by a prostacyclin analogue
Abstract
Although prostaglandins have been shown to inhibit the evolution of the nephritis in NZB/W mice, the mechanisms of this effect are unknown. To characterize such inhibition, we injected the prostacyclin (PGI2) analogue, beraprost, into NZB/W mice, using 0.5 mg, 1.0 mg or 5.0 mg beraprost/kg body weight of test animals three times in 1 week when the mice were 2 months old. Evaluation included measurement of urine albumin excretion, serological parameters and splenic T cell subset, as well as examination of renal histology by light and fluorescence microscopy. Mice given beraprost showed a marked decrease in urine albumin excretion and in glomerular hypercellularity compared with untreated controls. Maximal beneficial effects occurred when the dose was 5.0 mg/kg of beraprost. These effects correlated with a reduction of immune complex deposition in glomeruli. In addition, beraprost reduced serum levels of immunoglobulins and anti-double-stranded DNA antibodies, and decreased the number of helper (L3T4+) T cells in splenocytes. These results indicate that beraprost attenuates the nephritis of NZB/W mice, and that the source of this effect is the reduced production of autoantibodies and deposition of immune complexes in glomeruli.
Similar articles
-
Effect of prostaglandin E on immune complex nephritis in NZB/W mice.Lab Invest. 1979 Dec;41(6):531-7. Lab Invest. 1979. PMID: 159978
-
[Effects of YM-13650 on experimental nephritis in rats and mice].Nihon Yakurigaku Zasshi. 1991 Apr;97(4):199-207. doi: 10.1254/fpj.97.4_199. Nihon Yakurigaku Zasshi. 1991. PMID: 1831434 Japanese.
-
Rapamycin attenuates the severity of established nephritis in lupus-prone NZB/W F1 mice.Nephrol Dial Transplant. 2008 Sep;23(9):2768-76. doi: 10.1093/ndt/gfn216. Epub 2008 Apr 29. Nephrol Dial Transplant. 2008. PMID: 18445640
-
Nuclease deficiencies promote end-stage lupus nephritis but not nephritogenic autoimmunity in (NZB × NZW) F1 mice.Immunol Cell Biol. 2011 Jan;89(1):90-9. doi: 10.1038/icb.2010.75. Epub 2010 Jun 15. Immunol Cell Biol. 2011. PMID: 20548325 Review.
-
Beraprost: a review of its pharmacology and therapeutic efficacy in the treatment of peripheral arterial disease and pulmonary arterial hypertension.Drugs. 2002;62(1):107-33. doi: 10.2165/00003495-200262010-00005. Drugs. 2002. PMID: 11790158 Review.
Cited by
-
Therapeutics in renal disease: the road ahead for antiproliferative targets.Nephron Exp Nephrol. 2006;103(1):e6-15. doi: 10.1159/000090138. Epub 2005 Dec 7. Nephron Exp Nephrol. 2006. PMID: 16340240 Free PMC article.
-
A multinational phase IIb/III trial of beraprost sodium, an orally active prostacyclin analogue, in patients with primary glomerular disease or nephrosclerosis (CASSIOPEIR trial), rationale and study design.BMC Nephrol. 2014 Sep 19;15:153. doi: 10.1186/1471-2369-15-153. BMC Nephrol. 2014. PMID: 25233856 Free PMC article. Clinical Trial.
-
Orally active prostacyclin analogue beraprost sodium in patients with chronic kidney disease: a randomized, double-blind, placebo-controlled, phase II dose finding trial.BMC Nephrol. 2015 Oct 16;16:165. doi: 10.1186/s12882-015-0130-5. BMC Nephrol. 2015. PMID: 26475266 Free PMC article. Clinical Trial.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases